Smoking cessation treatment for COPD smokers: The role of pharmacological interventions

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 79, Issue 1, 2013, Pages 27-32

  Jimenez Ruiz C A ^a,b   Fagerstrom K O ^a,c  

^a not available ^*

^b Unidad Especializada en Tabaquismo ^*  (Spain)

^c Fagerström Consulting   (Sweden)

Author keywords

Bupropion; COPD smokers; High doses of nicotine replacement therapy; Nicotine replacement therapy; Pharmacological treatment; Smoking; Varenicline

Indexed keywords

AMFEBUTAMONE; NICOTINE GUM; NORTRIPTYLINE; VARENICLINE; ANTIDEPRESSANT AGENT; BUSPIRONE; NICOTINE; PLACEBO; SERTRALINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; HUMAN; NICOTINE REPLACEMENT THERAPY; REVIEW; SMOKING; SMOKING CESSATION; SMOKING CESSATION PROGRAM; TOBACCO DEPENDENCE; TREATMENT DURATION; ANXIETY DISORDER; COGNITIVE BEHAVIORAL THERAPY; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG MEGADOSE; DRUG SAFETY; EXERCISE; FORCED EXPIRATORY VOLUME; HIGH RISK POPULATION; META ANALYSIS (TOPIC); MONOTHERAPY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION;

EID: 84878318353     PISSN: 11220643     EISSN: 2465101X     Source Type: Journal    
DOI: 10.4081/monaldi.2013.106     Document Type: Review

References (40)

1. 1: The Lung Health Study. JAMA 1994; 272: 1497-1505.
2. Tønnesen P, Mikkelsen KL. Routine smoking cessation with 4 nicotine regiments in a lung clinic. Eur Respir J 2000; 16: 714-722.
3. Tønnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD, using nicotine sublingual tablets and behavioral support. Chest 2006; 130: 334-42. (Pubitemid 44266998)
4. Sundblad BM, Larsson K, Nathell L. High rates of smoking abstinence in COPD patients: smoking cessation by hospitalization. Nicotine Tob Res 2008; 10: 883-90. (Pubitemid 351974069)
5. Tonnessen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE-trial. Eur Respir J 1999; 13: 238-246. (Pubitemid 29086814)
6. Jorenby DE, Smith SS, Fiore MC, et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995; 274: 1347-1352.
7. Hughes JR, Lesmes GR, Hatsukami DK, et al. Are higher doses of nicotine replacement more effective for smoking cessation. Nicotine Tob Res 1999; 1: 169-174.
8. Fagerstrom KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology 1993; 111: 271-277. (Pubitemid 23165255)
9. Kornitzer M, Boutsen M, Dramaix M, Thijs JK, Gusstavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med 1995; 24: 41-47.
10. Puska P, Korhonen H, Vartiainen E. Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tob Control 1995; 4: 231-235.
11. Stead LF, Perera R, Bullen C, Mant D, Lancaster T www.cochrane.org/ reviews/en/ab000146.html. Access 6 April 2012.
12. Killen JD, Robinson TN, Ammerman S, et al. Randomised clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J Consult Clin Psychol 2004; 72: 729- 735.
13. Piper ME, Federman EB, McCarthy DE, et al. Efficacy of bupropion alone and in combination with nicotine gum. Nicotine Tob Res 2007; 9: 947-54. (Pubitemid 47354822)
14. Hurt R. Clinical Implications of Long-Term Nicotine Use, in Ferrence R, Slade J, Room R, Pope M (eds). Nicotine and Public Health. Washington, DC: American Public Health Association; 2000: 389-409.
15. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco use and dependence: 2008 update. Clinical practice guideline, Rockville MD. US.Deparment of Health and Human Service. May 2008.
16. Lerman C, Shields PG, Wileyto EP, et al. Effects of dopamine transporter and receptor polymorphins on smoking cessation in a bupropion clinical trial. Health Psychol 2003; 22: 541-8. (Pubitemid 37243689)
17. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) 2003; 168: 347-358. (Pubitemid 36920920)
18. Tashkin DP, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-5. (Pubitemid 32488814)
19. Wagena EJ, Knispchild PG, Huibers MJ, et al. Efficacy of bupropion and nortryptiline for smoking cessation among people at risk for or with COPD. Arch Intern Med 2005; 165: 2286-92. (Pubitemid 41549926)
20. th Annual Conference of the Society for Research of Nicotine and Tobacco. Seattle. Washington. 2001.
21. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. The Cochrane database of systematic reviews. 2004 Issue 4 Art No: CD 000031.
22. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcam MJ, et al. Bupropion SR for pharmacologic relapse prevention after smoking cessation. A randomised controlled trial. Ann Intern Med 2001; 135: 423-33 (Pubitemid 32845867)
23. Tapper A, Knney SL, Nashimi R. Nicotine activation of alpha4 receptors: sufficient for reward, tolerance, and sensitization. Science 2004; 306: 1029-1032. (Pubitemid 39482905)
24. Zierler-Brown SL, Kyle JA. Oral varenicline for smoking cessation. Ann Pharmacother 2007; 41: 95-99. (Pubitemid 46145962)
25. Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011; 139: 591-9.
26. Jiménez-Ruiz CA, Ramos Pinedo A, Cicero Guerrero A, et al. Characterisitics of COPD smokers and effectiveness and safety of smoking cessation medications. Nicotine Tob Res 2012; 14: 1035-9. doi: 10.1093/ntr/nts001.
27. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011 Feb 16; (2): CD006103.
28. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA 2006; 296: 64-71.
29. Hajek P, Tønnesen P, Arteaga C, Russ C, Tonstad S. Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment. Addiction 2009; 104: 1597-602.
30. Fiore MC, Baker TB. Clinical practice. Treating smokers in the health care setting. N Engl J Med 2011; 365: 1222-31.
31. Stead LF, Lancaster T. Interventions to reduce harm from continued tobacco use. Cochrane database System Review 2007; 18 (3) CD 005231.
32. Carpenter MJ, Hughes JR, Solomon LJ, Callas PW. Both smoking reduction with nicotine replacement therapy and motivational advice increase future cessation among smokers unmotivated to quit. J Consult Clin Psychol 2004; 72: 371-381. (Pubitemid 38679635)
33. Batra A, Klinger K, Landfeldt B, Friederich H, Westin A, Danielsson T. Smoking reduction treatment with a 4 mg nicotine gum: a double-blind, randomized, placebo-controlled study. Clin Pharmacol Ther 2005; 78: 689-696. (Pubitemid 41773644)
34. Rennard SI, Glover E, Leischow S, et al. Efficacy of nicotine inhaler in smoking reduction: a double-blind, randomized trial. Nicotine & Tob Res 2006; 8: 555-564. (Pubitemid 44263589)
35. Jiménez Ruiz CA, Solano S, Alonso Viteri S, Barrueco Ferrero M, Torrecilla M, Hernández Mezquita M. Harm Reduction - A Treatment Approach for Resistant Smokers with Tobacco-Related symptoms. Respiration 2002; 69: 452-455.
36. Hughes J, Rennard S, Fingar J, Talbot SK, Callas PW, Fagerstrom KO. Efficacy of Varenicline to Prompt Quit Attempts in Smokers Not Currently Trying to Quit: A Randomized Placebo-Controlled Trial. Nicotine Tob Res 2011; 13: 955-64. Epub 2011 Jun 7.
37. Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji AR. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. Arch Intern Med 2011; 171: 770-7.
38. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Mölken MPMH. Long term effectiveness and costeffectiveness of smoking cessation interventions in patients with COPD. Thorax 2010; 65: 711-8.
39. Strassmann R, Bausch B, Spaar A, et al. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J 2009; 34: 634-40.
40. Jimenez Ruiz CA, Riesco Miranda JA, et al. Recomendaciones para el tratamiento del tabaquismo en fumadores con EPOC. Arch Bronconeumol In press.